Literature DB >> 23094026

Epithelial mesenchymal transition and pancreatic tumor initiating CD44+/EpCAM+ cells are inhibited by γ-secretase inhibitor IX.

Vindhya Palagani1, Mona El Khatib, Uta Kossatz, Przemyslaw Bozko, Martin R Müller, Michael P Manns, Till Krech, Nisar P Malek, Ruben R Plentz.   

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with a high rate of metastasis. Recent studies have indicated that the Notch signalling pathway is important in PDAC initiation and maintenance, although the specific cell biological roles of the pathway remain to be established. Here we sought to examine this question in established pancreatic cancer cell lines using the γ-secretase inhibitor IX (GSI IX) to inactivate Notch. Based on the known roles of Notch in development and stem cell biology, we focused on effects on epithelial mesenchymal transition (EMT) and on pancreatic tumor initiating CD44+/EpCAM+ cells. We analyzed the effect of the GSI IX on growth and epithelial plasticity of human pancreatic cancer cell lines, and on the tumorigenicity of pancreatic tumor initiating CD44+/EpCAM+ cells. Notably, apoptosis was induced after GSI IX treatment and EMT markers were selectively targeted. Furthermore, under GSI IX treatment, decline in the growth of pancreatic tumor initiating CD44+/EpCAM+ cells was observed in vitro and in a xenograft mouse model. This study demonstrates a central role of Notch signalling pathway in pancreatic cancer pathogenesis and identifies an effective approach to inhibit selectively EMT and suppress tumorigenesis by eliminating pancreatic tumor initiating CD44+/EpCAM+ cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23094026      PMCID: PMC3477166          DOI: 10.1371/journal.pone.0046514

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  48 in total

1.  Tumor-suppressive pathways in pancreatic carcinoma.

Authors:  E Rozenblum; M Schutte; M Goggins; S A Hahn; S Panzer; M Zahurak; S N Goodman; T A Sohn; R H Hruban; C J Yeo; S E Kern
Journal:  Cancer Res       Date:  1997-05-01       Impact factor: 12.701

Review 2.  Pancreatic cancer.

Authors:  Manuel Hidalgo
Journal:  N Engl J Med       Date:  2010-04-29       Impact factor: 91.245

3.  Inhibition of gamma-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma.

Authors:  Ruben Plentz; Ji-Sun Park; Andrew D Rhim; Daniel Abravanel; Aram F Hezel; Sreenath V Sharma; Sushma Gurumurthy; Vikram Deshpande; Candia Kenific; Jeffrey Settleman; Pradip K Majumder; Ben Z Stanger; Nabeel Bardeesy
Journal:  Gastroenterology       Date:  2009-01-14       Impact factor: 22.682

Review 4.  Notch signaling in solid tumors.

Authors:  Ute Koch; Freddy Radtke
Journal:  Curr Top Dev Biol       Date:  2010       Impact factor: 4.897

Review 5.  Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways.

Authors:  Naoko Takebe; Pamela J Harris; Ronald Q Warren; S Percy Ivy
Journal:  Nat Rev Clin Oncol       Date:  2010-12-14       Impact factor: 66.675

6.  Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells.

Authors:  Bin Bao; Zhiwei Wang; Shadan Ali; Dejuan Kong; Yiwei Li; Aamir Ahmad; Sanjeev Banerjee; Asfar S Azmi; Lucio Miele; Fazlul H Sarkar
Journal:  Cancer Lett       Date:  2011-04-03       Impact factor: 8.679

7.  Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions.

Authors:  R H Hruban; N V Adsay; J Albores-Saavedra; C Compton; E S Garrett; S N Goodman; S E Kern; D S Klimstra; G Klöppel; D S Longnecker; J Lüttges; G J Offerhaus
Journal:  Am J Surg Pathol       Date:  2001-05       Impact factor: 6.394

8.  Characterization of a new primary human pancreatic tumor line.

Authors:  M H Tan; N J Nowak; R Loor; H Ochi; A A Sandberg; C Lopez; J W Pickren; R Berjian; H O Douglass; T M Chu
Journal:  Cancer Invest       Date:  1986       Impact factor: 2.176

9.  Notch and Kras reprogram pancreatic acinar cells to ductal intraepithelial neoplasia.

Authors:  Jean-Paul De La O; Lyska L Emerson; Jessica L Goodman; Scott C Froebe; Benjamin E Illum; Andrew B Curtis; L Charles Murtaugh
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-21       Impact factor: 11.205

10.  Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo.

Authors:  M A Goodell; K Brose; G Paradis; A S Conner; R C Mulligan
Journal:  J Exp Med       Date:  1996-04-01       Impact factor: 14.307

View more
  24 in total

1.  Epithelial-mesenchymal transition: a new target in anticancer drug discovery.

Authors:  Fabrizio Marcucci; Giorgio Stassi; Ruggero De Maria
Journal:  Nat Rev Drug Discov       Date:  2016-01-29       Impact factor: 84.694

Review 2.  Altered gene products involved in the malignant reprogramming of cancer stem/progenitor cells and multitargeted therapies.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  Mol Aspects Med       Date:  2013-08-29

3.  Notch Signaling Pathway in Pancreatic Cancer Progression.

Authors:  Jia Ma; Jun Xia; Lucio Miele; Fazlul H Sarkar; Zhiwei Wang
Journal:  Pancreat Disord Ther       Date:  2013-05-30

4.  Inhibition of Notch signaling alters the phenotype of orthotopic tumors formed from glioblastoma multiforme neurosphere cells but does not hamper intracranial tumor growth regardless of endogene Notch pathway signature.

Authors:  Karina Kristoffersen; Mette Kjølhede Nedergaard; Mette Villingshøj; Rehannah Borup; Helle Broholm; Andreas Kjær; Hans Skovgaard Poulsen; Marie-Thérése Stockhausen
Journal:  Cancer Biol Ther       Date:  2014-04-22       Impact factor: 4.742

5.  Prospective study of the safety and efficacy of a pancreatic cancer stem cell vaccine.

Authors:  Mao Lin; Yuan-Ying Yuan; Shu-Peng Liu; Juan-Juan Shi; Xin-An Long; Li-Zhi Niu; Ji-Bing Chen; Qiao Li; Ke-Cheng Xu
Journal:  J Cancer Res Clin Oncol       Date:  2015-04-10       Impact factor: 4.553

Review 6.  Tackling the cancer stem cells - what challenges do they pose?

Authors:  Diwakar R Pattabiraman; Robert A Weinberg
Journal:  Nat Rev Drug Discov       Date:  2014-07       Impact factor: 84.694

Review 7.  Molecular mechanisms of epithelial-mesenchymal transition.

Authors:  Samy Lamouille; Jian Xu; Rik Derynck
Journal:  Nat Rev Mol Cell Biol       Date:  2014-03       Impact factor: 94.444

Review 8.  Stem cell-directed therapies in pancreatic cancer.

Authors:  Rachit Kumar; Avani Dholakia; Zeshaan Rasheed
Journal:  Curr Probl Cancer       Date:  2013-10-08       Impact factor: 3.187

9.  Gastric tumor-initiating CD44+ cells and epithelial-mesenchymal transition are inhibited by γ-secretase inhibitor DAPT.

Authors:  Lu-Chun Li; Dong-Lin Wang; Yong-Zhong Wu; Wei-Qi Nian; Zhi-Juan Wu; Yan Li; Hui-Wen Ma; Jiang-He Shao
Journal:  Oncol Lett       Date:  2015-09-18       Impact factor: 2.967

Review 10.  Pancreatic cancer stem cell markers and exosomes - the incentive push.

Authors:  Sarah Heiler; Zhe Wang; Margot Zöller
Journal:  World J Gastroenterol       Date:  2016-07-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.